Sanofi

Regeneron, Sanofi tease potential expanded collaboration for Dupixent follow-ons

Endpoints News · 2 days ago

Why Sanofi Stock Is Falling Thursday - Sanofi (NASDAQ:SNY)

Benzinga · 2 days ago

Regeneron Addresses Melanoma Trial Failure, Sanofi Negotiations, M&A Strategy on Q2 Earnings Call

Precision Medicine Online · 2 days ago

Sanofi (SNY) Faces Stock Decline Amid CEO's Warning on Drug Pipe

GuruFocus · 2 days ago

Sanofi Beats on Q2 Earnings & Sales, Stock Down on Pipeline Setbacks

Yahoo Finance · 3 days ago

European Stocks Advance on Busy Earnings Day; Sanofi Slumps

Bloomberg.com · 3 days ago

Sanofi’s new CEO wants more ‘realistic view’ of Phase 3 go/no-go decisions

BioSpace · 3 days ago

Sanofi raises outlook as quarterly Dupixent sales cross €5B for first time

FirstWord Pharma · 3 days ago

Sanofi Slides After Q2 as Investors Focus on Pipeline Cuts Despite Higher 2026 Outlook

Quiver Quantitative · 3 days ago

Sanofi Shares Slide After CEO Signals Challenges to Fill Drug Pipeline

WSJ · 3 days ago

Press Release: Sanofi’s half-year financial report for 2026

Yahoo Finance Singapore · 3 days ago

Sanofi lifts 2026 outlook as dupilumab tops €5bn

EMJ · 3 days ago

Earnings call transcript: Sanofi beats Q2 2026 estimates but stock falls premarket

Investing.com · 3 days ago

Sanofi drops two more programmes in R&D clear-out

pharmaphorum · 3 days ago

Sanofi (Nasdaq: SNY) lifts H1 2026 sales but books large amlitelimab hit

Stock Titan · 3 days ago

Sanofi’s New CEO Raises Outlook As Blockbuster Skin Drug Surges

Bloomberg.com · 3 days ago

Sanofi drug pipeline worries, Dupixent dependence shake shares

The Mighty 790 KFGO · 3 days ago

Sanofi (NASDAQ: SNY) raises 2026 guidance on sharp Q2 sales and EPS gains

Stock Titan · 3 days ago

Sanofi axes two more inflammatory-disease drugs

European Biotechnology Magazine · 3 days ago

Sanofi lifts annual outlook after Q2 sales beat but stock dips

Investing.com · 3 days ago